Shares of Johnson & Johnson
JNJ,
+0.80%

gained 0.8% in premarket trading on Wednesday after the company said it will receive more than $1 billion from the U.S. government to manufacture 100 million doses of its investigational COVID-19 vaccine. The vaccine will be provided at a “global not-for-profit basis for emergency pandemic use,” J&J said. The company’s vaccine candidate recently entered the Phase 1/2a clinical trial, which is taking place in Belgium and the U.S. J&J’s stock is up 0.9% year-to-date, while the S&P 500
SPX,
+0.52%

has gained 2.3%.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here